Noting that rivaroxaban did not show much difference in efficacy across the dose range tested in this study, the authors, led by Dr Giancarlo Agnelli (University of Perugia, Italy), suggest that ...

In the fall of 2018, the 2.5-mg dose of the name-brand rivaroxaban was introduced to the U.S., when it was approved for prevention of major adverse cardiovascular events in CAD and PAD.

However, compared with aspirin, rivaroxaban was associated with higher rates of major bleeding (risk difference, 0.9 percentage points; 95% CI, –0.1 to 3.7) and intracranial hemorrhage (risk ...

A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose aspirin revealed a link between rivaroxaban and higher rates of major bleeding and ...